{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T23:36:56Z","timestamp":1720568216292},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T00:00:00Z","timestamp":1562976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","award":["The RESOLUTE US Clinical Trial was funded by Medtr"],"award-info":[{"award-number":["The RESOLUTE US Clinical Trial was funded by Medtr"]}],"id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the long\u2010term safety and efficacy of the Resolute zotarolimus\u2010eluting stent (R\u2010ZES).<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>The R\u2010ZES has been associated with low rates of adverse events over short\u2010intermediate term follow\u2010up. However, reliable assessment of the safety and efficacy of any implanted device requires long\u2010term evaluation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The RESOLUTE US trial was a prospective, observational study conducted at 116\u2009U.S. sites and enrolled patients with de novo coronary lesions. Patients were followed clinically for 5 years with independent event adjudication and data monitoring.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1,402 patients (1,573 lesions) were enrolled; 34% had diabetes mellitus and 75% had ACC type B2\/C lesions. The 5\u2010year rate of target lesion failure (TLF) was 12.3%, target lesion revascularization was 6.5%, target vessel myocardial infarction was 3.2%, and cardiac death was 4.1%. Dual antiplatelet therapy usage was 94% at 1 year and 47% at 5 years, with a 0.1% and 0.5% respective incidence of definite or probable stent thrombosis. The 5\u2010year rate of TLF was 16.9% among patients with diabetes mellitus and 14.7% in patients with at least one small (\u22642.5 mm) vessel treated. Covariates independently associated with 5\u2010year TLF in multivariable analysis included diabetes mellitus (odds ratio [OR] 1.89, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001), prior coronary artery bypass grafting (OR 2.28, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001), prior myocardial infarction (OR 1.85, <jats:italic>p<\/jats:italic> = .002), and smaller reference vessel diameter (OR 1.75, <jats:italic>p<\/jats:italic> = .004).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Results from the fully adjudicated and monitored RESOLUTE US trial demonstrate long\u2010term 5\u2010year safety and efficacy of the R\u2010ZES stent among a relatively low\u2010risk population of patients, including a 0.5% rate of stent thrombosis at 5 years.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ccd.28392","type":"journal-article","created":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T13:15:13Z","timestamp":1563023713000},"page":"1067-1073","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long\u2010term (5\u2010year) clinical evaluation of the Resolute zotarolimus\u2010eluting coronary stent: The RESOLUTE US clinical trial"],"prefix":"10.1002","volume":"95","author":[{"given":"Ajay J.","family":"Kirtane","sequence":"first","affiliation":[{"name":"NewYork\u2010Presbyterian Hospital\/Columbia University Medical Center  New York New York"},{"name":"Clinical Trials Center Cardiovascular Research Foundation  New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan C.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine  Stanford California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ball","sequence":"additional","affiliation":[{"name":"EMH Elyria Medical Center  Elyria Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Carr","sequence":"additional","affiliation":[{"name":"Tyler Cardiac and Endovascular Center and East Texas Medical Center  Tyler Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"O'Shaughnessy","sequence":"additional","affiliation":[{"name":"Saint Vincent Heart Center of Indiana  Indianapolis Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mauri","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital and Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minglei","family":"Liu","sequence":"additional","affiliation":[{"name":"Medtronic PLC  Santa Rosa California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin B.","family":"Leon","sequence":"additional","affiliation":[{"name":"NewYork\u2010Presbyterian Hospital\/Columbia University Medical Center  New York New York"},{"name":"Clinical Trials Center Cardiovascular Research Foundation  New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,7,13]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2012.02.014"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.4244\/EIJY15M07_07"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2009.03.013"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.111.967802"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.03.005"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.03.015"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.002230"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2016.11.004"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2013.07.009"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2013.04.011"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jcin.2017.02.029","article-title":"Biodegradable polymer biolimus\u2010eluting stents versus durable polymer everolimus\u2010eluting stents in patients with coronary artery disease: final 5\u2010year report from the COMPARE II Trial (abluminal biodegradable polymer biolimus\u2010eluting stent versus durable polymer everolimus\u2010eluting stent)","volume":"10","author":"Vlachojannis GJ","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2016.02.020"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.05.004"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2011.10.013"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.28392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.28392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ccd.28392","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.28392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T09:15:00Z","timestamp":1693991700000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.28392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,13]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1002\/ccd.28392"],"URL":"https:\/\/doi.org\/10.1002\/ccd.28392","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,13]]},"assertion":[{"value":"2019-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}